European Medical Device Company Signs Multiyear Agreement to Use OmniComm’s TrialMaster for Ophthalmological Research
Fort Lauderdale, Fla. (GLOBE NEWSWIRE) -- A major European medical device company specializing in ophthalmology has signed a three-year agreement to use TrialMaster EDC from OmniComm Systems, Inc., a global provider of clinical data management technology. Under the terms of the agreement, the medical device company has committed to use TrialMaster and related OmniComm services to build and manage multiple clinical studies.
The device company selected TrialMaster for a variety of reasons, including OmniComm’s user-friendly technology and customer service. The Data Management staff valued TrialMaster’s advanced functionality, which will enable them to access image exams through programmable hyperlinks in individual fields in the CRF. Additionally, imaging metadata can be batch loaded into TrialMaster, removing the need for redundant data entry. The device company also appreciated TrialMaster’s ease of use for sites, along with the simplicity of the study design tools, which are important factors since the research team will build its own studies in TrialMaster.
“OmniComm has experienced record growth in Europe over the past 12 months, especially in the Medical Device sector,” said Stephen Johnson, president and CEO of OmniComm. “Although there are a lot of similarities between device and drug trials, there can be subtle regulatory and operational differences that can significantly affect the design and execution of the trial. This agreement is a testament to TrialMaster’s fit for purpose in these sometimes very complex medical device trials.”
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies, research organizations drive efficiency in clinical development, better manage risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from more than 6,000 clinical trials. Please visit www.omnicomm.com for more information, and follow OmniComm on Twitter: @OmniCommSystems, on LinkedIn: @OmniComm Systems and Facebook: @OmniComm Systems, Inc.
Contact InfoKuno van der Post, Ph.D. OmniComm Systems, Inc. +1.954.473.1254KvanderPost@omnicomm.com
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
